Reuters logo
BRIEF-Biogen’s Imraldi granted positive opinion by committee for medicinal products for human use
June 23, 2017 / 2:06 PM / 6 months ago

BRIEF-Biogen’s Imraldi granted positive opinion by committee for medicinal products for human use

June 23 (Reuters) - Biogen Inc

* Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by committee for medicinal products for human use

* Secondary endpoints demonstrated that Imraldi has a comparable safety and immunogenicity profile to Humira

* Primary endpoint of phase III study, ACR20 response at week 24, was met, demonstrating equivalent efficacy to Humira Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below